Total Payments
$4,137
2024 Payments
$499.37
Companies
27
Transactions
173
Medicare Patients
2,942
Medicare Billing
$831,373
Payment Breakdown by Category
Food & Beverage$2,620 (63.3%)
Consulting$1,050 (25.4%)
Education$467.46 (11.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,620 | 159 | 63.3% |
| Consulting Fee | $1,050 | 1 | 25.4% |
| Education | $467.46 | 13 | 11.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Melinta Therapeutics, LLC | $1,153 | 7 | $0 (2022) |
| ABBVIE INC. | $743.09 | 66 | $0 (2024) |
| Insmed, Inc. | $491.12 | 18 | $0 (2024) |
| ViiV Healthcare Company | $295.11 | 16 | $0 (2024) |
| Merck Sharp & Dohme LLC | $256.18 | 13 | $0 (2024) |
| Allergan, Inc. | $172.59 | 10 | $0 (2020) |
| Gilead Sciences, Inc. | $139.96 | 8 | $0 (2023) |
| Ferring Pharmaceuticals Inc. | $138.36 | 3 | $0 (2024) |
| Astellas Pharma US Inc | $135.31 | 7 | $0 (2024) |
| Janssen Products, LP | $89.00 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $499.37 | 30 | ABBVIE INC. ($179.88) |
| 2023 | $647.18 | 35 | ABBVIE INC. ($241.67) |
| 2022 | $534.04 | 30 | ABBVIE INC. ($166.70) |
| 2021 | $1,579 | 28 | Melinta Therapeutics, LLC ($1,050) |
| 2020 | $69.88 | 4 | Gilead Sciences, Inc. ($19.58) |
| 2019 | $270.93 | 14 | Merck Sharp & Dohme Corporation ($61.44) |
| 2018 | $288.49 | 18 | Allergan Inc. ($66.82) |
| 2017 | $248.06 | 14 | Allergan Inc. ($53.52) |
All Payment Transactions
173 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: Infectious Diseases | ||||||
| 12/03/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE | Food and Beverage | In-kind items and services | $9.04 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/12/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/23/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $7.24 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/22/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $29.35 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/11/2024 | Shionogi Inc | Fetroja (Drug) | Education | In-kind items and services | $13.20 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/02/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/26/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $26.09 | General |
| Category: GI | ||||||
| 09/18/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: HIV | ||||||
| 09/05/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/29/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $17.45 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/21/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE | Food and Beverage | In-kind items and services | $8.36 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/25/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: HIV | ||||||
| 07/23/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE | Food and Beverage | In-kind items and services | $6.77 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/11/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/26/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $8.12 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/05/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: HIV | ||||||
| 05/21/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: HIV | ||||||
| 05/08/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE | Food and Beverage | In-kind items and services | $12.74 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/09/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE | Food and Beverage | In-kind items and services | $6.55 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/19/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE | Food and Beverage | In-kind items and services | $7.29 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/07/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $28.11 | General |
| Category: HIV | ||||||
| 03/05/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $6.04 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/23/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $33.11 | General |
| Category: HIV | ||||||
| 02/19/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $28.88 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 524 | 13,512 | $557,280 | $213,798 |
| 2022 | 13 | 605 | 13,037 | $515,777 | $213,821 |
| 2021 | 15 | 759 | 7,108 | $398,296 | $157,346 |
| 2020 | 16 | 1,054 | 67,792 | $715,755 | $246,408 |
Total Patients
2,942
Total Services
101,449
Medicare Billing
$831,373
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0875 | Injection, dalbavancin, 5 mg | Office | 2023 | 25 | 12,700 | $292,100 | $148,696 | 50.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 241 | 257 | $128,500 | $32,000 | 24.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 36 | 269 | $70,478 | $12,808 | 18.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 73 | 102 | $19,545 | $5,652 | 28.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 38 | 62 | $17,277 | $5,587 | 32.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 75 | 79 | $14,615 | $4,351 | 29.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 31 | $8,153 | $2,736 | 33.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $6,612 | $1,968 | 29.8% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2022 | 33 | 12,300 | $282,900 | $149,010 | 52.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 209 | 235 | $117,500 | $34,043 | 29.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 44 | 112 | $29,344 | $5,412 | 18.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 69 | 77 | $15,081 | $4,625 | 30.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 38 | 55 | $14,465 | $4,226 | 29.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 38 | 49 | $13,533 | $4,219 | 31.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 66 | 75 | $13,875 | $3,949 | 28.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 17 | $6,120 | $2,012 | 32.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $7,572 | $2,010 | 26.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $5,610 | $1,780 | 31.7% |
| 99451 | Telephone or internet assessment with written report by consulting physician, 5 minutes or more | Facility | 2022 | 39 | 45 | $3,825 | $1,198 | 31.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 12 | 12 | $3,675 | $758.57 | 20.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 16 | 33 | $2,277 | $578.25 | 25.4% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2021 | 17 | 6,100 | $140,300 | $77,470 | 55.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 287 | 310 | $133,610 | $45,914 | 34.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 115 | 144 | $26,640 | $7,701 | 28.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 29 | 132 | $31,416 | $7,253 | 23.1% |
About Dr. David Letzer, MD
Dr. David Letzer, MD is a Infectious Disease healthcare provider based in Brookfield, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255382529.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Letzer, MD has received a total of $4,137 in payments from pharmaceutical and medical device companies, with $499.37 received in 2024. These payments were reported across 173 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($2,620).
As a Medicare-enrolled provider, Letzer has provided services to 2,942 Medicare beneficiaries, totaling 101,449 services with total Medicare billing of $831,373. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Brookfield, WI
- Active Since 05/12/2006
- Last Updated 01/23/2025
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1255382529
Products in Payments
- Orbactiv (Drug) $1,081
- DALVANCE (Drug) $652.80
- Arikayce (Drug) $474.88
- SYMTUZA (Drug) $191.05
- AVYCAZ (Drug) $188.33
- REBYOTA (Biological) $138.36
- CABENUVA (Biological) $83.85
- TEFLARO (Drug) $74.55
- ZERBAXA (Drug) $73.81
- PIFELTRO (Drug) $66.73
- DOVATO (Drug) $64.40
- CRESEMBA (Drug) $58.19
- EGRIFTA (Drug) $56.08
- ISENTRESS (Drug) $53.47
- Cresemba (Drug) $52.13
- TRIUMEQ (Drug) $48.26
- DIFICID (Drug) $47.91
- APRETUDE (Biological) $47.01
- VIBATIV (Drug) $44.93
- VOWST (Biological) $44.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.